154 related articles for article (PubMed ID: 18386881)
21. The angiotensin IV/AT4 receptor.
Chai SY; Fernando R; Peck G; Ye SY; Mendelsohn FA; Jenkins TA; Albiston AL
Cell Mol Life Sci; 2004 Nov; 61(21):2728-37. PubMed ID: 15549174
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and AT2 receptor-binding properties of angiotensin II analogues.
Rosenström U; Sköld C; Lindeberg G; Botros M; Nyberg F; Hallberg A; Karlén A
J Pept Res; 2004 Nov; 64(5):194-201. PubMed ID: 15485557
[TBL] [Abstract][Full Text] [Related]
23. Insulin-regulated aminopeptidase/placental leucil Aminopeptidase (IRAP/P-lAP) and angiotensin IV-forming activities are modified in serum of rats with breast cancer induced by N-methyl-nitrosourea.
Pilar Carrera M; Ramírez-Expósito MJ; Dueñas B; Dolores Mayas M; Jesús García M; De la Chica S; Cortés P; Ruíz-Sanjuan M; Martínez-Martos JM
Anticancer Res; 2006; 26(2A):1011-4. PubMed ID: 16619500
[TBL] [Abstract][Full Text] [Related]
24. Mutagenesis of the AT1 receptor reveals different binding modes of angiotensin II and [Sar1]-angiotensin II.
Santos EL; Pesquero JB; Oliveira L; Paiva AC; Costa-Neto CM
Regul Pept; 2004 Jul; 119(3):183-8. PubMed ID: 15120479
[TBL] [Abstract][Full Text] [Related]
25. Bicyclic tripeptide mimetics with reverse turn inducing properties.
Johannesson P; Lindeberg G; Tong W; Gogoll A; Karlén A; Hallberg A
J Med Chem; 1999 Feb; 42(4):601-8. PubMed ID: 10052967
[TBL] [Abstract][Full Text] [Related]
26. Assessment of biological activity of novel peptide analogues of angiotensin IV.
Gard PR; Olivier G; Golding B; Bourner C; Dang T; Haliru H; Higgins E; Kimberley H; Loginova O; Madhavi S; Ryan D
J Pharm Pharmacol; 2011 Apr; 63(4):565-71. PubMed ID: 21401609
[TBL] [Abstract][Full Text] [Related]
27. From angiotensin IV binding site to AT4 receptor.
Vanderheyden PM
Mol Cell Endocrinol; 2009 Apr; 302(2):159-66. PubMed ID: 19071192
[TBL] [Abstract][Full Text] [Related]
28. A novel amino-benzosuberone derivative is a picomolar inhibitor of mammalian aminopeptidase N/CD13.
Maiereanu C; Schmitt C; Schifano-Faux N; Le Nouën D; Defoin A; Tarnus C
Bioorg Med Chem; 2011 Sep; 19(18):5716-33. PubMed ID: 21843945
[TBL] [Abstract][Full Text] [Related]
29. Angiotensin IV interacts with a juxtamembrane site on AT(4)/IRAP suggesting an allosteric mechanism of enzyme modulation.
Caron AZ; Arguin G; Guillemette G
Regul Pept; 2003 May; 113(1-3):9-15. PubMed ID: 12686456
[TBL] [Abstract][Full Text] [Related]
30. First synthesis of alpha-aminoalkyl-(N-substituted)thiocarbamoyl-phosphinates: inhibitors of aminopeptidase N (APN/CD13) with the new zinc-binding group.
Grzywa R; Oleksyszyn J
Bioorg Med Chem Lett; 2008 Jul; 18(13):3734-6. PubMed ID: 18524593
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of bioactive saponins and triterpenoidal aglycons for their binding properties on human endothelin ETA and angiotensin AT1 receptors.
Caballero-George C; Vanderheyden PM; Okamoto Y; Masaki T; Mbwambo Z; Apers S; Gupta MP; Pieters L; Vauquelin G; Vlietinck A
Phytother Res; 2004 Sep; 18(9):729-36. PubMed ID: 15478202
[TBL] [Abstract][Full Text] [Related]
32. 3-Amino-2-hydroxyamides and related compounds as inhibitors of methionine aminopeptidase-2.
Sheppard GS; Wang J; Kawai M; BaMaung NY; Craig RA; Erickson SA; Lynch L; Patel J; Yang F; Searle XB; Lou P; Park C; Kim KH; Henkin J; Lesniewski R
Bioorg Med Chem Lett; 2004 Feb; 14(4):865-8. PubMed ID: 15012983
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and preliminary evaluation of novel pyrrolidine derivatives as matrix metalloproteinase inhibitors.
Cheng XC; Wang Q; Fang H; Tang W; Xu WF
Eur J Med Chem; 2008 Oct; 43(10):2130-9. PubMed ID: 18362041
[TBL] [Abstract][Full Text] [Related]
34. Effects of angiotensin II and its metabolites in the rat coronary vascular bed: is angiotensin III the preferred ligand of the angiotensin AT2 receptor?
van Esch JH; Oosterveer CR; Batenburg WW; van Veghel R; Jan Danser AH
Eur J Pharmacol; 2008 Jul; 588(2-3):286-93. PubMed ID: 18511032
[TBL] [Abstract][Full Text] [Related]
35. Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase.
Albiston AL; McDowall SG; Matsacos D; Sim P; Clune E; Mustafa T; Lee J; Mendelsohn FA; Simpson RJ; Connolly LM; Chai SY
J Biol Chem; 2001 Dec; 276(52):48623-6. PubMed ID: 11707427
[TBL] [Abstract][Full Text] [Related]
36. Tachyphylactic properties of angiotensin II analogs with bulky and hydrophobic substituents at the N-terminus.
Motta SC; Poletti EF; Souza SE; Correa SA; Jubilut GN; Paiva AC; Shimuta SI; Nakaie CR
J Pept Res; 2003 Nov; 62(5):227-32. PubMed ID: 14531846
[TBL] [Abstract][Full Text] [Related]
37. Novel potent nonpeptide aminopeptidase N inhibitors with a cyclic imide skeleton.
Miyachi H; Kato M; Kato F; Hashimoto Y
J Med Chem; 1998 Jan; 41(3):263-5. PubMed ID: 9464355
[No Abstract] [Full Text] [Related]
38. Enzyme-catalyzed formation of beta-peptides: beta-peptidyl aminopeptidases BapA and DmpA acting as beta-peptide-synthesizing enzymes.
Heck T; Kohler HP; Limbach M; Flögel O; Seebach D; Geueke B
Chem Biodivers; 2007 Sep; 4(9):2016-30. PubMed ID: 17886858
[TBL] [Abstract][Full Text] [Related]
39. Synergistic modulation of cystinyl aminopeptidase by divalent cation chelators.
Demaegdt H; Laeremans H; De Backer JP; Mosselmans S; Le MT; Kersemans V; Michotte Y; Vauquelin G; Vanderheyden PM
Biochem Pharmacol; 2004 Sep; 68(5):893-900. PubMed ID: 15294452
[TBL] [Abstract][Full Text] [Related]
40. Short pseudopeptides containing turn scaffolds with high AT2 receptor affinity.
Georgsson J; Rosenström U; Wallinder C; Beaudry H; Plouffe B; Lindeberg G; Botros M; Nyberg F; Karlén A; Gallo-Payet N; Hallberg A
Bioorg Med Chem; 2006 Sep; 14(17):5963-72. PubMed ID: 16753301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
